Maurice Zauderer - Jan 27, 2022 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Role: President and CEO, Director
Signature: /s/ Scott E. Royer, Attorney-in-Fact for Maurice Zauderer
Stock symbol: VCNX
Transactions as of: Jan 27, 2022
Transactions value $: $1,999,999
Form type: 4
Date filed: 1/31/2022, 03:23 PM
Next filing: Apr 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VCNX	Common Stock	Purchase	$2M	+1.8M	+164.14%	$1.11	2.9M	Jan 27, 2022	By Vaccinex (Rochester), L.L.C.	F2
holding	VCNX	Common Stock						178K	Jan 27, 2022	Direct
holding	VCNX	Common Stock						213K	Jan 27, 2022	By Jeremy C. Zauderer Trust	F1
holding	VCNX	Common Stock						212K	Jan 27, 2022	By Jordan M. Zauderer Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	VCNX	Stock Option (Right to Buy)						2.59K	Jan 27, 2022	Common Stock	2.59K	$14.90	Direct	F3
holding	VCNX	Stock Option (Right to Buy)						2.59K	Jan 27, 2022	Common Stock	2.59K	$14.90	Direct	F3
holding	VCNX	Stock Option (Right to Buy)						3.33K	Jan 27, 2022	Common Stock	3.33K	$7.10	Direct	F3
holding	VCNX	Stock Option (Right to Buy)						20K	Jan 27, 2022	Common Stock	20K	$4.29	Direct	F4
holding	VCNX	Stock Option (Right to Buy)						28.4K	Jan 27, 2022	Common Stock	28.4K	$6.68	Direct	F5
holding	VCNX	Stock Option (Right to Buy)						14K	Jan 27, 2022	Common Stock	14K	$2.93	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
F2	Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3	Exercisable in full as of the date of this report.
F4	This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 15, 2019 grant date.
F5	This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
F6	This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.